BSAVA Formulary: Your questions answered

A new edition of the BSAVA Small Animal Formulary has been published. Ian Ramsey explains what is in and what is out of this new version

Diagnosis and treatment of canine hypoadrenocorticism

Canine hypoadrenocorticism (Addison’s disease), the ‘great pretender’ of internal medicine, is a disease that should be frequently considered as a differential diagnosis of several clinical presentations, albeit it is less commonly the actual cause of the clinical signs. Hypoadrenocorticism cannot be diagnosed on clinical signs alone and further investigations are always required. There have been some interesting new ideas about diagnostic options for this condition and new treatment options are available for both acute and chronic therapy of the condition in dogs. It is therefore pertinent to review the causes, diagnosis and treatment of hypoadrenocorticism in dogs

Management of Addison's disease in dogs

No abstract available

Hypoadrenocorticism in an aged cat

A 13-year-old, female, neutered, domestic longhair cat was referred to the hospital with a two-month history of fluctuating weakness, lethargy, inappetence and intermittently soft stools. Physical examination noted variable mentation, mild tachycardia with poor pulse quality and a body condition score of 1/9. In-house haematology and biochemistry abnormalities included a mild neutrophilia, hyponatraemia, and decreased Na:K ratio of 24 and isosthenuric urine (1.012). The cat was admitted to the hospital for intravenous fluid therapy and management of its electrolyte abnormalities. A low basal cortisol (36 nmol/l) was found on analysis of a stored serum sample, and further investigations confirmed the diagnosis of hypoadrenocorticism. Treatment was implemented initially with hydrocortisone and dexamethasone and continued long term with desoxycorticosterone pivalate and oral prednisolone. More than one year since diagnosis, the cat is clinically well and stable on treatment

Validation and determination of a reference interval for Canine HbA1c using an immunoturbidimetric assay

Background: Hemoglobin A1c (HbA1c) provides a reliable measure of glycemic control over 2–3 months in human diabetes mellitus. In dogs, presence of HbA1c has been demonstrated, but there are no validated commercial assays. Objective: The purpose of the study was to validate a commercially available automated immunoturbidimetric assay for canine HbA1c and determine an RI in a hospital population. Methods: The specificity of the assay was assessed by inducing glycosylation in vitro using isolated canine hemoglobin, repeatability by measuring canine samples 5 times in succession, long term inter-assay imprecision by measuring supplied control materials, stability using samples stored at 4°C over 5 days and −20°C over 8 weeks, linearity by mixing samples of known HbA1c in differing proportions, and the effect of anticoagulants with paired samples. An RI was determined using EDTA-anticoagulated blood samples from 60 nondiabetic hospitalized animals of various ages and breeds. Hemoglobin A1c was also measured in 10 diabetic dogs. Results: The concentration of HbA1c increased proportionally with glucose concentration in vitro. For repeat measurements, the CV was 4.08% (range 1.16–6.10%). Samples were stable for 5 days at 4°C. The assay was linear within the assessed range. Heparin- and EDTA-anticoagulated blood provided comparable results. The RI for HbA1c was 9–18.5 mmol/mol. There was no apparent effect of age or breed on HbA1c. In diabetic dogs, HbA1c ranged from 14 to 48 mmol/mol. Conclusions: The assay provides a reliable method for canine HbA1c measurement with good analytic performance

Backcountry Cell Phone Vignettes: Connected and Disconnected

Ian Ramsey writes that while technology can make adventurers safer, it also corrupts people’s direct experience and attention; and how ten middle schoolers gradually disengage from technology in the New Hampshire mountains. Douglas Balmain has remained loyal to map and compass, so he finds it disorienting when a companion navigates using an app

Recombinant Surface Glycoproteins of Feline Leukaemia Virus

Feline leukaemia virus (FeLV) is a major cause of degenerative and proliferative diseases of myeloid, lymphoid and erythroid origin in domestic cats. The envelope of FeLV, which is a typical retrovirus, is studded with a transmembrane protein (TM) that anchors an external surface glycoprotein (SU). The FeLV SU (gp70) carries both neutralising epitopes and subgroup phenotypic determinants. FeLV occurs naturally in 3 subgroups, which are defined by a superinfection interference assay, suggesting that three FeLV cellular receptors exist, one for each subgroup. The regions of SU which determine the A/C phenotype have been defined as lying in a small variable region towards the amino terminus of the protein